- £3.60bn
- £4.86bn
- $3.35bn
UK's Hikma gains on strong first-half profit
UK's Hikma Pharma holds annual outlook, prepares for US generic drug tariffs (updated)
UK Stocks-Factors to watch on August 6 (updated)
UK's Hikma Pharmaceuticals posts half-year profit rise as turnaround progresses
UK's Hikma Pharmaceuticals H1 revenue, profit rise on strong branded drugs growth
Hikma Pharmaceutical - Directorate change
Hikma Pharmaceutical - Half-year Financial Report
UK Stocks-Factors to watch on August 6
Hikma Pharmaceutical - Holding(s) in Company
Hikma Pharmaceutical - Holding(s) in Company
Hikma Pharmaceutical - Holding(s) in Company
Brief: Hikma Launches Diazepam Injection, USP In US
Brief: Hikma Launches XCOPRI In UAE
Focus: US progesterone supplies tighten as menopause treatment demand grows
Hikma Pharmaceutical - Holding(s) in Company
Hikma Pharmaceutical - Holding(s) in Company
UK Stocks-Factors to watch on June 5 (updated)
UK Stocks-Factors to watch on June 5
US Supreme Court backs generic drugmaker in 'skinny label' patent case (updated)